About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

32.01 +0.89 (+2.86%)
Delayed Quote Updated: 11:39 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗
Via Chartmill
News headline image
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
From Pharvaris N.V.
Via GlobeNewswire
News headline image
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? ↗
This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Annual General Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
From Pharvaris N.V.
Via GlobeNewswire
News headline image
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies. 
Via The Motley Fool
News headline image
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Outlines 2026 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.